NASDAQ:ERAS Erasca (ERAS) Stock Price, News & Analysis $1.21 -0.05 (-3.97%) Closing price 04:00 PM EasternExtended Trading$1.22 +0.01 (+0.41%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Erasca Stock (NASDAQ:ERAS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Erasca alerts:Sign Up Key Stats Today's Range$1.17▼$1.2750-Day Range$1.21▼$1.9552-Week Range$1.04▼$3.45Volume1.55 million shsAverage Volume1.78 million shsMarket Capitalization$342.75 millionP/E RatioN/ADividend YieldN/APrice Target$4.83Consensus RatingBuy Company OverviewErasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Read More… Remove Ads Erasca Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreERAS MarketRank™: Erasca scored higher than 73% of companies evaluated by MarketBeat, and ranked 221st out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingErasca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageErasca has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Erasca's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Erasca are expected to grow in the coming year, from ($0.73) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Erasca's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.21% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 22.5, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently decreased by 2.24%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.21% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 22.5, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently decreased by 2.24%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.63 News SentimentErasca has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Erasca this week, compared to 2 articles on an average week.Search Interest3 people have searched for ERAS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Erasca to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have not sold or bought any company stock.Percentage Held by Insiders21.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Erasca's insider trading history. Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Stock News HeadlinesErasca (ERAS) Gets a Buy from J.P. MorganMarch 30, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Erasca (ERAS)March 27, 2025 | markets.businessinsider.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 3, 2025 | Paradigm Press (Ad)Raymond James Begins Coverage on Erasca (NASDAQ:ERAS)March 27, 2025 | americanbankingnews.comRaymond James Initiates Coverage of Erasca (ERAS) with Outperform RecommendationMarch 26, 2025 | msn.comErasca Announces Three Poster Presentations at the 2025 AACR Annual MeetingMarch 25, 2025 | globenewswire.comErasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial ResultsMarch 21, 2025 | finanznachrichten.deErasca reports Q4 EPS (11c), consensus (13c)March 21, 2025 | markets.businessinsider.comSee More Headlines ERAS Stock Analysis - Frequently Asked Questions How have ERAS shares performed this year? Erasca's stock was trading at $2.51 at the beginning of 2025. Since then, ERAS shares have decreased by 51.8% and is now trading at $1.21. View the best growth stocks for 2025 here. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) issued its quarterly earnings data on Thursday, March, 20th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. When did Erasca IPO? Erasca (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share. How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Erasca own? Based on aggregate information from My MarketBeat watchlists, some other companies that Erasca investors own include Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings3/20/2025Today4/03/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERAS CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$4.83 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+299.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.26% Return on Assets-34.97% Debt Debt-to-Equity RatioN/A Current Ratio11.00 Quick Ratio11.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book0.58Miscellaneous Outstanding Shares283,266,000Free Float221,941,000Market Cap$342.75 million OptionableOptionable Beta1.22 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ERAS) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.